Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS

Go back to Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS

Ionis Pharmaceuticals (IONS) PT Lowered to $68 at Laidlaw

October 18, 2021 7:53 AM EDT

Laidlaw analyst Yale Jen lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $68.00 (from $78.00) while maintaining a Buy rating.

Tofersen in SOD1-ALS VALOR Trial Failed to Meet Primary Endpoint but Substantial Knowledge Learned... More